Kevin Kalish is the COO of Enclear Therapies, a biotechnology company that has developed a novel platform for delivering therapeutics to hard-to-reach areas of the central nervous system by circulating the Cerebrospinal Fluid. Enclear's innovative technology holds promise as a means to treat a variety of neuro-oncological and neurodegenerative diseases. In this conversation with Kevin, we discuss the technology, its initial indications, its promises, and the challenges that must be overcome to get there.